Clinically relevant reduction of lamotrigine concentrations by carbamazepine

European Psychiatry

Volumn 18, Issue 1, 2003, Pages 42-

  Koch, Horst J ^a   Szecsey, Alexander ^a   Vogel, Matthias ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CITALOPRAM; ETIRACETAM; LAMOTRIGINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPLEX PARTIAL SEIZURE; CONCENTRATION RESPONSE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG WITHDRAWAL; HUMAN; MALE; ORGANIC PSYCHOSYNDROME; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0037299064     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(02)00002-0     Document Type: Article

References (7)

1. Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000;56:299-304.
2. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002;24:91-103.
3. Harden C. Safety profile of levetiracetam. Epilepsia 2001;42(Suppl 4):36-9.
4. Janowsky DS. New treatments of bipolar disorder. Curr Psychiatry Rep 1999;1: 111-3.
5. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur J Clin Pharmacol 2002 [Online 23 January 2002].
6. Shah MM, Balaran R. Effect of phenobarbitone, carbamazepine and sodium valproate on the elimination kinetics of acetaminophen. Indian J Pharmacol 1999;31:311-4.
7. Willmore LJ. Lamotrigine. Expert Rev Neurotherapeutics 2001;1: 33-42.